Michael’s practice is focused on intellectual property (“IP”) law, with an emphasis on patent law in the pharmaceutical and biotechnology industries.
Michael regularly advises clients on issues arising throughout the product life cycle, including providing freedom to operate and patent validity opinions to aid with product development, representing clients in proceedings under the Patented Medicines (Notice of Compliance) Regulations to facilitate product launch, and representing clients in post-market patent disputes.
Prior to joining Blaney McMurtry LLP, Michael acted as the in-house Canadian IP counsel for a multinational pharmaceutical company. In this role Michael supported the Business Development, Market Access, Marketing, Portfolio and Regulatory Groups, advising senior management on IP, commercial and regulatory issues relating to both the generic and branded business.